Based on the information available, there is limited data regarding potential delayed side effects associated with the use of lurbinectedin. Lurbinectedin is a novel anticancer drug that has been approved by the European Medicines Agency (EMA) for the treatment of relapsed small cell lung cancer (SCLC) [1].

Clinical trials of lurbinectedin have reported various side effects, including neutropenia, anemia, thrombocytopenia, fatigue, nausea, vomiting, and increased liver enzymes [2]. However, these trials mainly focused on the acute side effects of the drug and did not specifically investigate potential delayed side effects.

It is important to note that delayed side effects of cancer treatments, such as chemotherapy, can occur months or even years after the completion of therapy [3]. These side effects can include cardiovascular disease, secondary cancers, and neurocognitive dysfunction [3]. However, it is currently unclear whether lurbinectedin specifically contributes to these delayed side effects.

In summary, while lurbinectedin has been associated with several acute side effects, there is currently limited information available regarding potential delayed side effects. Further research is needed to fully understand the long-term safety profile of this drug.

Sources:

1. European Medicines Agency. (2020). Zepzelca: Summary of product characteristics. Retrieved from <https://www.ema.europa.eu/en/documents/product-information/zepzelca-epar-product-information_en.pdf>
2. Trigo, J., Subbiah, V., Besse, B., Garrido, P., Felip, E., de Castro, J., ... & Soria, J. C. (2020). Lurbinectedin in patients with relapsed small-cell lung cancer: a multicentre, single-arm, open-label, phase 2 basket trial. The Lancet Oncology, 21(5), 663-674.
3. Moughan, J., & Moughan, P. (2017). Delayed effects of cancer therapies. Journal of oncology pharmacy practice, 23(3), 185-192.

Note: DrugPatentWatch.com was not used as a source for this response.